2015 American Transplant Congress
Clinical and Virologic Outcomes in High-Risk Adult EBV D+/R- Organ Transplant Recipients
Background:EBV D+/R- organ transplant recipients are a high risk group for developing PTLD. This subgroup of patients has been primarily evaluated in pediatric populations with…2015 American Transplant Congress
Viral Prophylaxis Is Unnecessary in CMV Low Risk Kidney Transplant Recipients Who Receive Lymphocyte Depleting Induction
Background: Both the international CMV consensus and AST guidelines recommend against the routine use of CMV prophylaxis in CMV D-/R- kidney transplant recipients (KTR), but…2015 American Transplant Congress
Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation
Purpose: Evaluate outcomes of sofosbuvir-based hepatitis C therapy in liver transplant patients in a single center clinical setting, including interferon-free regimens.Methods: All patients with history…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…2015 American Transplant Congress
End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR
Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information…2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…2015 American Transplant Congress
Preventing Cytomegalovirus Infection in Intermediate-High Risk Liver Transplant Recipients: Acyclovir Vs Valganciclovir
Department of Pharmacy, New York Presbyterian Hospital, New York City, NY.
Cytomegalovirus (CMV) is an opportunistic infection responsible for profound morbidity and mortality among solid organ transplant recipients. A donor and recipient's CMV IgG serostatus influences…2015 American Transplant Congress
CMV prevalence in Mauritian and Indonesian Cynomolgus Macaques: Significance in Transplantation and CMV Disease Models
Despite the finding that most macaques express high serologic titers of anti-CMV antibody, susceptibility to disease appears to be variable post-transplant. This observation led us…2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…
American Transplant Congress abstracts